Plans to support microbicide trial
This was revealed yesterday by Professor Quarraisha Abdool Karim, one of the researchers who conducted the trial of the microbicide gel under the banner of the Centre for the AIDS programme of Research in SA (Caprisa)
A factory site to manufacture tenofovir gel has already been identified on the KwaZulu-Natal south coast by a public-private company, Professor Abdool Karim told a high level scientific meeting convened in Durban to assess Caprisa’s scientific outputs.
A number of trials are also planned to support the first trial, which found that the infection rate among the women who received the tenofovir microbicide was 39% lower than those who did not get the gel.
A large trial currently underway in a number of African countries will compare the efficacy of tenofovir gel with tenofovir tablets, as well as comparing tenofovir with another ARV called Truvada.
Caprisa is also waiting for permission to run an implentation trial to see how the tenofovir microbicide can be integrated into normal family planning services.
It also aims to run a trial to look at whether women who have used the tenofovir gel will develop resistance to the medicine, which would have implications for them should they become HIV positive.
However, an interrogation of the results by Caprisa scientists over the past year has raised even more questions.
Dr Vivek Naranbhai reported that the women who became infected with HIV during the trial had a relatively high level of vaginal inflammation. He suggested that it would be important to see whether anti-inflammatories could assist to reduce HIV transmission.
His colleague, Dr Sengeziwe Sibeko reported that it was possible that the tenofovir gel had only protected women if their partners had relatively low viral load in their semen.
‘Certainly we urgently need further research to see whether this is the case, but unfortunately we don’t have the funds yet to do so,’ said Sibeko.
Meanwhile, Science and Technology Minister Naledi Pandor complimented Caprisa for its research prowess.
‘I am so tired of Africa being a recipient of things,’ said Pandor. ‘We need to become a source of solutions. We need to move beyond being a resource-based to a knowledge-based economy.’
She added that she was working to encourage a bio-technology economy in South Africa along the lines of India and Brazil.
‘We have set aside land in the Western Cape for a biotechnology park, supported by government,’ said Pandor.
Author
-
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
View all posts
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Plans to support microbicide trial
by Health-e News, Health-e News
June 6, 2011